• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S.

作者信息

Huynh Angela, Arnold Donald M, Michael James V, Clare Rumi, Smith James W, Daka Mercy, Ianosi-Irimie Monica, McKenzie Steven E, Kelton John G, Nazy Ishac

机构信息

Department of Medicine, Michael G. DeGroote School of Medicine.

McMaster Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada.

出版信息

Blood Adv. 2023 Jan 24;7(2):246-250. doi: 10.1182/bloodadvances.2022007336.

DOI:10.1182/bloodadvances.2022007336
PMID:35377937
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9860431/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a6/9860431/3829de958377/BLOODA_ADV-2022-007336-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a6/9860431/3829de958377/BLOODA_ADV-2022-007336-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a6/9860431/3829de958377/BLOODA_ADV-2022-007336-gr1.jpg

相似文献

1
Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S.接种Ad26.COV2.S疫苗的患者中疫苗诱导的血栓性血小板减少症（VITT）抗体的特征
Blood Adv. 2023 Jan 24;7(2):246-250. doi: 10.1182/bloodadvances.2022007336.
2
Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies.Ad26.COV2.S 相关疫苗诱导的免疫性血栓性血小板减少症（VITT）的持续存在和 VITT 抗体的特异性检测。
Am J Hematol. 2022 May;97(5):519-526. doi: 10.1002/ajh.26488. Epub 2022 Feb 21.
3
Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccine.生物物理研究并未揭示人类 PF4 与 Ad26.COV2.S 疫苗之间的直接相互作用。
J Thromb Haemost. 2024 Apr;22(4):1046-1055. doi: 10.1016/j.jtha.2023.12.020. Epub 2023 Dec 29.
4
Vaccine-induced immune thrombotic thrombocytopenia in a male after Ad26.COV2.S vaccination presenting as cerebral venous sinus thrombosis.一名男性接种Ad26.COV2.S疫苗后出现疫苗诱导的免疫性血栓性血小板减少症，表现为脑静脉窦血栓形成。
Platelets. 2022 Jul 4;33(5):797-800. doi: 10.1080/09537104.2022.2071854. Epub 2022 May 9.
5
Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine.检测对 Ad26.COV2.S 疫苗无应答的 HIV-1 感染个体中预先存在的针对 Ad26 的中和抗体。
Infection. 2023 Dec;51(6):1657-1667. doi: 10.1007/s15010-023-02035-6. Epub 2023 Apr 17.
6
Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States.美国 Ad26.COV2.S（强生）新型冠状病毒病 2019（COVID-19）疫苗预防 COVID-19 住院和进展为高疾病严重程度的有效性。
Clin Infect Dis. 2022 Oct 3;75(Suppl 2):S159-S166. doi: 10.1093/cid/ciac439.
7
Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge.单剂量Ad26.COV2.S疫苗在美国德尔塔变种激增之前及期间预防新冠病毒感染和住院的持久性
JAMA Netw Open. 2022 Mar 1;5(3):e222959. doi: 10.1001/jamanetworkopen.2022.2959.
8
Relative Effectiveness of Coronavirus Disease 2019 Vaccination and Booster Dose Combinations Among 18.9 Million Vaccinated Adults During the Early Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Period-United States, 1 January 2022 to 31 March 2022.在 2022 年 1 月 1 日至 2022 年 3 月 31 日严重急性呼吸综合征冠状病毒 2 型奥密克戎早期期间，对 1890 万接种成年人中，新冠肺炎 2019 疫苗接种和加强针组合的相对有效性。
Clin Infect Dis. 2023 May 24;76(10):1753-1760. doi: 10.1093/cid/ciad063.
9
Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.医护人员中 mRNA-1273、BNT162b2 和 Ad26.COV2.S 新冠疫苗的抗体反应持久性比较。
Int J Infect Dis. 2022 Oct;123:183-191. doi: 10.1016/j.ijid.2022.08.022. Epub 2022 Aug 28.
10
Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US.接种 Ad26.COV2.S 后发生致命性疫苗诱导的免疫性血栓性血小板减少症（VITT）：首例美国以外的确诊病例。
Infection. 2022 Apr;50(2):531-536. doi: 10.1007/s15010-021-01712-8. Epub 2021 Oct 9.

引用本文的文献

1
VITT Pathophysiology: An Update.疫苗诱导的血栓性血小板减少症（VITT）的病理生理学：最新进展
Vaccines (Basel). 2025 Jun 17;13(6):650. doi: 10.3390/vaccines13060650.
2
Comparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccines.两种腺病毒载体新冠疫苗接种后疫苗诱导的免疫性血小板减少症和血栓形成病例的比较。
Commun Med (Lond). 2025 May 10;5(1):168. doi: 10.1038/s43856-025-00891-x.
3
Association of human leucocyte antigen loci with vaccine-induced immune thrombotic thrombocytopenia: Potential role of the interaction between platelet factor 4-derived peptides and MHC-II.

本文引用的文献

1
ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome.ChAdOx1与CAR和PF4相互作用，对伴有血小板减少的血栓形成综合征有影响。
Sci Adv. 2021 Dec 3;7(49):eabl8213. doi: 10.1126/sciadv.abl8213. Epub 2021 Dec 1.
2
Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia.疫苗诱导免疫性血栓性血小板减少症的抗体表位。
Nature. 2021 Aug;596(7873):565-569. doi: 10.1038/s41586-021-03744-4. Epub 2021 Jul 7.
3
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.
人类白细胞抗原基因座与疫苗诱导的免疫性血栓性血小板减少症的关联：血小板因子4衍生肽与MHC-II相互作用的潜在作用
Br J Haematol. 2025 Jan;206(1):290-295. doi: 10.1111/bjh.19838. Epub 2024 Oct 27.
4
Genotoxicity and safety pharmacology of the rVSVInd(GML)-mspSGtc vaccine against SARS-CoV-2 in Sprague-Dawley rats and Beagle dogs.rVSVInd(GML)-mspSGtc 疫苗对 SARS-CoV-2 的遗传毒性和安全药理学在 Sprague-Dawley 大鼠和比格犬中的研究。
Arch Toxicol. 2024 Jul;98(7):2185-2197. doi: 10.1007/s00204-024-03746-x. Epub 2024 Apr 12.
5
The Function of ASK1 in Sepsis and Stress-Induced Disorders.ASK1 在脓毒症和应激相关紊乱中的作用。
Int J Mol Sci. 2023 Dec 22;25(1):213. doi: 10.3390/ijms25010213.
6
Transient Autoreactive PF4 and Antiphospholipid Antibodies in COVID-19 Vaccine Recipients.新冠疫苗接种者体内的短暂性自身反应性PF4和抗磷脂抗体
Vaccines (Basel). 2023 Dec 14;11(12):1851. doi: 10.3390/vaccines11121851.
7
Autoimmune Heparin-Induced Thrombocytopenia.自身免疫性肝素诱导的血小板减少症
J Clin Med. 2023 Nov 3;12(21):6921. doi: 10.3390/jcm12216921.
8
Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)-Insights from Clinical Cases, In Vitro Studies and Murine Models.疫苗诱导的免疫性血小板减少症和血栓形成（VITT）——来自临床病例、体外研究和小鼠模型的见解
J Clin Med. 2023 Sep 22;12(19):6126. doi: 10.3390/jcm12196126.
9
Vaccine-induced immune thrombotic thrombocytopenia.疫苗诱导的免疫性血栓性血小板减少症。
Blood. 2023 Apr 6;141(14):1659-1665. doi: 10.1182/blood.2022017696.
10
Vaccine-induced immune thrombotic thrombocytopenia.疫苗诱导的免疫性血栓性血小板减少症。
Best Pract Res Clin Haematol. 2022 Sep;35(3):101381. doi: 10.1016/j.beha.2022.101381. Epub 2022 Sep 13.
美国 2021 年 3 月 2 日至 4 月 21 日 Ad26.COV2.S 疫苗接种后出现脑静脉窦血栓形成伴血小板减少的病例报告。
JAMA. 2021 Jun 22;325(24):2448-2456. doi: 10.1001/jama.2021.7517.
4
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination.接种 ChAdOx1 nCoV-19 疫苗后对血小板因子 4 的病理性抗体。
N Engl J Med. 2021 Jun 10;384(23):2202-2211. doi: 10.1056/NEJMoa2105385. Epub 2021 Apr 16.
5
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.接种 ChAdOx1 nCov-19 疫苗后发生血栓性血小板减少症。
N Engl J Med. 2021 Jun 3;384(22):2092-2101. doi: 10.1056/NEJMoa2104840. Epub 2021 Apr 9.
6
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.ChAdOx1新冠疫苗接种后的血栓形成和血小板减少症
N Engl J Med. 2021 Jun 3;384(22):2124-2130. doi: 10.1056/NEJMoa2104882. Epub 2021 Apr 9.
7
Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia.鉴定与肝素诱导的血小板减少症中致病性抗体结合的血小板因子 4 氨基酸。
J Thromb Haemost. 2019 Feb;17(2):389-399. doi: 10.1111/jth.14369.
8
Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Circumsporozoite Protein Antigens.合格的生物层干涉亲和力测量可区分与环子孢子蛋白抗原的抗体相互作用的异质性。
J Immunol. 2018 Aug 15;201(4):1315-1326. doi: 10.4049/jimmunol.1800323. Epub 2018 Jul 13.
9
Development of a high-yield expression and purification system for platelet factor 4.血小板因子 4 的高效表达和纯化系统的开发。
Platelets. 2018 May;29(3):249-256. doi: 10.1080/09537104.2017.1378808. Epub 2017 Nov 27.
10
5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies.5B9，一种单克隆抗血小板因子 4/肝素 IgG，具有模仿肝素诱导的血小板减少症抗体的人 Fc 片段。
J Thromb Haemost. 2017 Oct;15(10):2065-2075. doi: 10.1111/jth.13786. Epub 2017 Sep 4.